Jagannath, Vinita http://orcid.org/0000-0001-6785-8181
Gerstenberg, Miriam
Correll, Christoph U.
Walitza, Susanne
Grünblatt, Edna
Funding for this research was provided by:
Swiss Government Excellence Scholarship (2014.0826)
Article History
Received: 12 April 2017
Accepted: 23 August 2017
First Online: 1 September 2017
Compliance with ethical standards
:
: Dr. Christoph U. Correll has been a consultant and/or advisor to or has received honoraria from: Alkermes, Allergan, Bristol-Myers Squibb, Gerson Lehrman Group, IntraCellular Therapies, Janssen/J&J, LB Pharma, Lundbeck, Medavante, Medscape, Neurocrine, Otsuka, Pfizer, ProPhase, Sunovion, Takeda, and Teva. He has provided expert testimony for Bristol-Myers Squibb, Janssen, and Otsuka. He served on a Data Safety Monitoring Board for Lundbeck and Pfizer. He received grant support from Takeda. Dr. Susanne Walitza has received lecture honoraria from Eli-Lilly, Astra Zeneca, Shire, and Opopharma in the last 5 years. Outside professional activities and interests are declared under the link of the University of ZurichExternalRef removed. The other authors declare no conflict of interest.
: This project was supported by the Swiss Government Excellence Scholarship (2014.0826) to VJ.